AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2019 GMT

WALTHAM, Mass.--(BUSINESS WIRE)--Dec 31, 2019--

ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 16,900 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan, or the Inducement Plan. The stock option was granted as an inducement material to the new employee’s becoming an employee of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The option has an exercise price of $5.46 per share, which is equal to the closing price of ImmunoGen’s common stock on the Nasdaq Global Select Market on December 23, 2019. The option will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to such employee’s continued employment with ImmunoGen on such vesting dates. The option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191231005179/en/

CONTACT: INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: ONCOLOGY PROFESSIONAL SERVICES HEALTH FINANCE CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: ImmunoGen Inc.

Copyright Business Wire 2019.

PUB: 12/31/2019 04:01 PM/DISC: 12/31/2019 04:01 PM

http://www.businesswire.com/news/home/20191231005179/en